Bacteriolytic therapy can generate a potent immune response against experimental tumors.

When spores of the anaerobic bacterium Clostridium novyi-NT are systemically injected into animals, they germinate exclusively within the hypoxic regions of cancers. The germinated bacteria destroy adjacent tumor cells but spare a rim of well oxygenated tumor cells that subsequently expand. Surprisingly, we found that approximately 30% of mice treated with such spores were cured of their cancers despite the viable tumor rim initially remaining after spore germination. The mechanism underlying this effect was shown to be immune-mediated, because cured animals rejected a subsequent challenge of the same tumor. Similar effects were observed in rabbits with intrahepatic tumors. It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors.

[1]  F. Heppner,et al.  The liquefaction (oncolysis) of malignant gliomas by a non pathogenic Clostridium , 2005, Acta Neurochirurgica.

[2]  Linhong Li,et al.  Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells , 2004, Cancer Gene Therapy.

[3]  S. Rosenberg,et al.  clinical implications of basic research Shedding Light on Immunotherapy for Cancer , 2004 .

[4]  Megan Sykes,et al.  Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Parmigiani,et al.  Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-microtubule Agents , 2004, Cancer biology & therapy.

[6]  M. Peyromaure,et al.  T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival , 2004, BJU international.

[7]  L. Turka,et al.  Autoimmunity heats up , 2003, Nature Medicine.

[8]  M. Czuczman,et al.  Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Bert Vogelstein,et al.  Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Lukas Hunziker,et al.  Dendritic cell–induced autoimmune heart failure requires cooperation between adaptive and innate immunity , 2003, Nature Medicine.

[11]  D. O’Briain,et al.  Autopsy findings in an outbreak of severe systemic illness in heroin users following injection site inflammation: an effect of Clostridium novyi exotoxin? , 2003, Archives of pathology & laboratory medicine.

[12]  R. Wahl,et al.  Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose. , 2003, Cancer research.

[13]  E. Leung,et al.  Mouse B7-H3 induces antitumor immunity , 2003, Gene Therapy.

[14]  P. Lambin,et al.  Tumor-specific gene delivery using genetically engineered bacteria. , 2003, Current gene therapy.

[15]  M. Kersten,et al.  Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma , 2003, British Journal of Cancer.

[16]  E. Jaffee,et al.  Cancer Vaccines: An Old Idea Comes of Age , 2003, Cancer biology & therapy.

[17]  L. Emens.  A New Twist on Autologous Cancer Vaccines , 2003, Cancer biology & therapy.

[18]  Cancer Vaccine Collaborative 2002: opening address. , 2003, Cancer immunity.

[19]  Zihai Li,et al.  Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. , 2003, Cancer immunity.

[20]  Carl Nathan,et al.  Points of control in inflammation , 2002, Nature.

[21]  J. Salmon,et al.  Lethal outbreak of infection with Clostridium novyi type A and other spore-forming organisms in Scottish injecting drug users. , 2002, Journal of medical microbiology.

[22]  Thierry Boon,et al.  Tumor‐specific shared antigenic peptides recognized by human T cells , 2002, Immunological reviews.

[23]  C. Drake,et al.  Tumor immunology--towards a paradigm of reciprocal research. , 2002, Seminars in cancer biology.

[24]  AJ Giaccia,et al.  Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis , 2002, Gene Therapy.

[25]  R. Jain,et al.  Can engineered bacteria help control cancer? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A B Kay,et al.  Allergy and allergic diseases. First of two parts. , 2001, The New England journal of medicine.

[28]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[29]  D. Golenbock,et al.  Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. , 1999, Journal of immunology.

[30]  Samuel I. Miller,et al.  Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo , 1999, Nature Biotechnology.

[31]  Y. Kano,et al.  Construction of Escherichia coli-Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A. , 1997, Bioscience, biotechnology, and biochemistry.

[32]  C. Starnes,et al.  Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. , 1994, Pharmacology & therapeutics.

[33]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.